Respiration
Treatment of Reversible Airway Obstruction with Duovent. Principles and ...
The Combination of Fenoterol and Ipratropium Bromide in Bronchial Asthma: Comparison of the Acute Effects of Two Different DosagesBonsignore G. · Bellia V. · Peralta G. · Alessi N. · Migliara G.Istituto di Medicina Generale e Pneumologia, Università di Palermo, e Istituto di Fisiopatologia Respiratoria, Consiglio Nazionale delle Ricerche, Palermo, Italia
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: January 16, 2009
Issue release date: 1986
Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 0
ISSN: 0025-7931 (Print)
eISSN: 1423-0356 (Online)
For additional information: https://www.karger.com/RES
Abstract
Combinations of beta-stimulant and anticholinergic drugs have been advocated as a potentially useful tool in the treatment of reversible airway obstruction. We investigated the effectiveness and safety of a metered aerosol preparation delivering fenoterol 100 µg and ipratropium bromide 40 µg per puff: two dosages (2 puffs and 4 puffs) were used in 16 asthmatic patients, and their acute effects (up to 420 min) were investigated in a double-blind randomized trial. The results point out a reasonably good response to both dosages, with no notable difference between them as far as vital capacity, FEV1, MMEF and Vmax75 are concerned. This finding indicates the possibility of achieving a satisfactory bronchodilation at beta-stimulant dosages far lower than the standard ones commonly used and therefore minimizing the risk of untoward cardiovascular effects.
© 1986 S. Karger AG, Basel
Related Articles:
Article / Publication Details
Published online: January 16, 2009
Issue release date: 1986
Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 0
ISSN: 0025-7931 (Print)
eISSN: 1423-0356 (Online)
For additional information: https://www.karger.com/RES
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
